Bevacizumab and lung cancer: Eligible patients in daily practice;Bévacizumab et cancer bronchique: Population cible en pratique quotidienne

Revue des Maladies Respiratoires

Volumn 28, Issue 1, 2011, Pages 25-31

  Lagnien Gaume, V ^a   Jehl, J ^a,b   Manzoni, P ^a   Jacoulet, P ^a   Gainet Brun, M ^a   Metzger, F ^a,b   Pernet, D ^a   Polio, J C ^a   Pugin, J F ^a   Corgne, J ^a   Amoros, C ^a   Dalphin, J C ^a,b   Westeel, V ^a,b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

Bevacizumab; Chemotherapy; Non small cell lung cancer; Targeted agents; Tomodensitometric criteria

Indexed keywords

BEVACIZUMAB;

ARTICLE; CANCER PATIENT; CARDIOVASCULAR DISEASE; HUMAN; KAPPA STATISTICS; LUNG CANCER; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953122197     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmr.2010.05.016     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. Cancer J Clin 2007;57:43-66. (Pubitemid 46148091)
2. Hill C, Doyon F. La fréquence des cancers en France: mortalité en 2003, évolution depuis 1968 et cancers de l'enfant. Bull Cancer 2007;94:7-13. (Pubitemid 46232412)
3. Spiro Stephen G, Gould Mickaël K, Colice Gene L. Initial evaluation of the patient with lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes. Chest 2007;132:149-60.
4. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic and end results database. J Clin Oncol 2006;24:4539-44. (Pubitemid 46630948)
5. Blanchon F, Grivaux M, Collon T, et al. Épidémiologie du cancer bronchique primitif pris en charge dans les centres hospitaliers généraux français. Rev Mal Respir 2002;19:727-34. (Pubitemid 36019711)
6. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
7. Pérol M, Moro-Sibilot D. Chimiothérapie des cancers bronchiques non à petites cellules métastatiques. Rev Mal Respir 2005;22:131-6.
8. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91. (Pubitemid 41095154)
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
10. Reck M, Von Pawel J, Zatluokal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009;27:1227-34.
11. Reck M, Von Pawel J, Zatluokal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010;21:1804-9.
12. Autorisation de mise sur le marché du bévacizumab. 2009.
13. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-7. (Pubitemid 27260107)
14. Barlesi F, Balleyguier C, Besse B, Bonodeau F, Brenac F, Corneloup O, et al. Inter-and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Ann Oncol 2010, abstract 1014.
15. Hirsh V, Bennouna J, Kuo HP, Szima B, Gottfried M, Kunitsyn A, et al. Review of pulmonary haemorrhage (PH) in non-small cell lung cancer (NSCLC) patients receiving bevacizumab and cisplatin plus gemcitabine on protocol BO17704 (AVAIL). ECCO 2007.
16. Sandler A, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, et al. Retrospective evaluation of the clinical and radiogra phic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with carboplatin and paclitaxel plus bevacizumab. J Clin Oncol 2009;27:1405-12.
17. HAS, Commission de la transparence, avis du 14 mai 2008 concernant l'AVASTIN. 2008.
18. Azzoli CG, Baker SJ, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small cell lung cancer. J Clin Oncol 2009;27:6251-66.
19. Pavlakis N, Crino L, Dansin E, Griesinger FG, Isla D, Laskin J, et al. MO19390 (SAIL) study group: safety of bevacizumab (BV) - based therapy as first-line treatment of eligible non-small-cell lung cancer (NSCLC) patients (PTS). Ann Oncol 2008;19, abstract 232PD.
20. Wozniak AJ, Garst J, Jahanzeb M, Kosty M, Vidaver R, Beatty S, et al. Clinical outcomes (CO) for special populations of patients (PTS) with advanced non-small cell lung cancer (NSCLC): results from ARIES, a bevacizumab (BV) observational cohort study (OCS). J Thorac Oncol 2010;5:100.